PPT-Synthesis of Aspirin Experiment Six
Author : faustina-dinatale | Published Date : 2020-04-03
Therapeutic uses amp contraindication Aspirin act as an analgesic antipyretic Antiinflammatory also inhibit platelet aggregation amp prolongs bleeding time because
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document " Synthesis of Aspirin Experiment Six" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Synthesis of Aspirin Experiment Six: Transcript
Therapeutic uses amp contraindication Aspirin act as an analgesic antipyretic Antiinflammatory also inhibit platelet aggregation amp prolongs bleeding time because of its effect on GIT it is contraindicated in peptic . Aspirin. perhaps most popular medicinal agent ever discovered. 30 000 000 . lb. /year sold in the US. Antipyretic (reduces fever). Anti-inflammatory (reduces . swelling suppresses prostaglandin hormone). Chapter 14. Aspirin. Pharmaceutical products are often developed from substance found in a plant that has been used for traditional medicine.. Aspirin is one of these products.. Salicylic acid is the active substance that helps . Evaluating the Risks and Benefits. Most Frequently Used OTC Analgesics. Reasons Why These Drugs Are Widely Used. What Limits the Use of OTC Drugs?. Adverse Effects of OTC Analgesics. Efficacy of Aspirin in Headache. Understandings. Aspirin . Mild . analgesics function by intercepting the pain stimulus at the source, often by interfering with the production of substances that cause pain, swelling, or fever. . Aspirin . No aspirin (n = 7,335) JPPP Primary endpoint (CV death/MI/stroke) for aspirin vs. no aspirin: 2.8% vs. 3.0%, p = 0.54 CV death: 0.86 % vs. 0.78%, p = 0.89 ; nonfatal cerebrovascular disease: 1.65 Original Article Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism Timothy A. Brighton, M.B., B.S., John W. Eikelboom, M.B., B.S., Kristy Mann, M.Biostat., Rebecca Mister, M.Sc., Alexander Gallus, M.B., B.S., Paul Ockelford, M.B., Harry Gibbs, M.B., Wendy Hague, Ph.D., Denis Xavier, M.Sc., Rafael Diaz, M.D., Adrienne Kirby, M.Sc., John Simes, M.D., for the ASPIRE Investigators Primary Prevention ASCVD. Jennifer Bannon RN BSN MSHI. Table of Contents. Objectives . Cardiovascular Disease. Cardiovascular Disease (2). ABCS-Aspirin when appropriate. Anatomy of a Performance Measure. The Role of Aspirin Today. Our Good Old Friend Aspirin. Earlier Primary Prevention Trials: . Aspirin Favored for Serious Vascular Events. Physicians. '. Health Study. Contemporary Aspirin Clinical Trials. Laying the Foundations. 1. State the problem. What is the problem? This is typically stated in a question format.. EXAMPLE. : Will taking one aspirin per day for 60 days decrease blood pressure . in. Kathleen M. Buchheit, MD. Assistant Director, AERD Center. Allergy & Immunology. Brigham and Women’s Hospital. September 13, 2019. Conflict of Interest Disclosure . Relevant financial relationships with commercial interests in the preceding 12 months: Regeneron, Genentech. Primary endpoint . (CV death/MI/stroke) for aspirin vs. no aspirin: . 2.8% vs. 3.0%, . p = 0.54 . CV . death: 0.86. % vs. 0.78%, . p = 0.89. ; nonfatal . cerebrovascular . disease: 1.65. % vs. 1.64%, . 89 non-cardioembolic stroke detected by rapid platelet function analyzer Jose C NAVARRO MD MSc , Annabelle Y LAO MD , Maricar P YUMUL MD , Maria Leticia C ARAULLO MD , Johnny K LOKIN MD , Aleja March 28, 2022. Disclosures. Present Research/Grant Funding. Janssen/Johnson & Johnson. CSL Behring. SCAD Alliance. Baim. Institute. Patents and Stocks: . None. Equity: . nference. , Inc. . Dyad Medical. (n . = 6,589). SOCRATES. Primary outcome, death, MI or stroke, for ticagrelor vs. aspirin: . 6.7% . vs. 7.5%, HR = 0.89, 95% CI . 0.78-1.01. , . p = 0.07. Death: 1.0% vs. 0.9%, . p = 0.36; All . strokes: 5.9% vs. 6.8%, .
Download Document
Here is the link to download the presentation.
" Synthesis of Aspirin Experiment Six"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents